Open AccessEffects of atorvastatin and pravastatin on immune activation and T-cell function in antiretroviral therapy-suppressed HIV-1-infected patients
Author(s) -
Edgar Turner Overton,
Sarah Sterrett,
Andrew O. Westfall,
Shan M. Kahan,
Greer Burkholder,
Allan Zajac,
Paul Goepfert,
Anju Bansal
Publication year - 2014
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000000475
Subject(s) - pravastatin , atorvastatin , medicine , immune system , peripheral blood mononuclear cell , immunology , cd8 , statin , cd38 , t cell , cholesterol , biology , stem cell , biochemistry , genetics , cd34 , in vitro
This retrospective study was designed to assess statin effects on T-cell activation from HIV-infected individuals. Peripheral blood mononuclear cells from antiretroviral therapy suppressed HIV-infected individuals receiving atorvastatin or pravastatin were evaluated for T-cell activation, exhaustion and function. Atorvastatin was associated with a significant reduction in CD8 T-cell activation (HLA-DR, CD38/HLA-DR) and exhaustion (TIM-3, TIM-3/PD-1) whereas pravastatin had no effect. In contrast, pravastatin increased antigen specific interferon γ production. These results suggest a differential effect of statins on immune activation and function.